NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
PACB
Pacific Biosciences of California, Inc.
PACB has the edge over NVO overall, supported by stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
PACB Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
PACB's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
PACB PE Valuation
PACB has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
PACB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| High |
Analysts expect PACB's losses to shrink, with revenue growing.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the stronger earnings trend. Trailing diluted EPS is up 4.9% for NVO versus PACB down 127%.
PACB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$1.46 | -$0.19 |
| Q2 2024 | -$1.50 | -$0.15 |
| Q1 2024 | -$1.14 | +$0.25 |
| Q4 2023 | -$1.21 | +$0.19 |
| Q3 2023 | -$1.27 | +$0.07 |
| Q2 2023 | -$1.35 | -$0.43 |
| Q1 2023 | -$1.39 | -$0.58 |
| Q4 2022 | -$1.40 | -$0.51 |
PACB lost $0.40 per share over the past year, a smaller loss than the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over PACB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over PACB on profitability, with a higher operating margin.
PACB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $40.6M | +5.5% |
| Q2 2026 | $39M | -1.9% |
| Q1 2026 | $37.2M | +0.1% |
| Q4 2025 | $44.6M | +14% |
| Q3 2025 | $38.4M | -3.8% |
| Q2 2025 | $39.8M | +10% |
| Q1 2025 | $37.2M | -4.3% |
| Q4 2024 | $39.2M | -33% |
PACB's revenue is recovering but still below its 2023 peak: $41M last quarter, up 5.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -91% | +9.9 points |
| Q2 2026 | -114% | -1.6 points |
| Q1 2026 | -22% | +1132 points |
| Q4 2025 | -92% | +298 points |
| Q3 2025 | -101% | +59 points |
| Q2 2025 | -113% | +376 points |
| Q1 2025 | -1155% | -945 points |
| Q4 2024 | -390% | -240 points |
PACB's operating margin was −91% last quarter, up 9.9 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over PACB on cash generation, producing positive trailing cash flow while its opponent burns cash.
PACB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$38.6M | -$20M |
| Q2 2026 | -$37.1M | -$7.2M |
| Q1 2026 | -$47.7M | -$2.3M |
| Q4 2025 | -$19.9M | +$12.3M |
| Q3 2025 | -$18.6M | +$26.1M |
| Q2 2025 | -$29.9M | +$25.8M |
| Q1 2025 | -$45.4M | +$34.1M |
| Q4 2024 | -$32.3M | +$27.3M |
PACB has burned cash in almost every quarter: −$143M over the past year, against −$126M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over PACB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
PACB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +592K shares |
| 1 year | +3.5% | +10.4M shares |
| 3 years | +22% | +56.2M shares |
| 5 years | +45% | +96.1M shares |
| Available history | +100% | +155M shares |
PACB has 311M diluted shares, up 3.5% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
PACB Net Leverage
PACB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
PACB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.2 | Neutral |
| Stochastic | 50.9 | Neutral |
PACB's weekly RSI is 53 (neutral) and its Stochastic is 51 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
PACB PE vs Healthcare Sector
| Metric | PACB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
PACB has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
PACB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.15 | 8.4% below |
| 20 week MA | $1.69 | 17% above |
| 50 week MA | $1.67 | 18% above |
| 100 week MA | $1.57 | 25% above |
| 200 week MA | $4.13 | 52% below |
PACB has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
PACB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.24 | $27.1 | +418% |
| 2021 | $27.1 | $21.4 | -21% |
| 2022 | $21.4 | $8.49 | -60% |
| 2023 | $8.49 | $9.81 | +16% |
| 2024 | $9.81 | $1.86 | -81% |
| 2025 | $1.86 | $1.77 | -4.8% |
| 2026 YTD | $1.77 | $1.97 | +11% |
PACB has the edge over NVO on returns for 2026, with the stronger performance.